26 Mai 2016 Jahr - FDA announced required safety labeling changes for methadone and buprenorphine products when used by pregnant women for medication- assisted treatment (MAT) of opioid use disorder to ensure providers have complete information about the benefits and risks of these products. FDA approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence.
Zugefügt zum Band der Zeit:
Datum:
26 Mai 2016 Jahr
Jetzt
~ 9 years and 5 months ago